-
You must submit the settlement Proof form attached below, in order to participate in this settlement. There is a strict deadline of July 24, 2019 by which all claims must be submitted. The instructions for submitting are included in the Proof and the Notice files attached below for your download. DO NOT SEND THE FORMS TO THE SHAREHOLDERS FOUNDATION, INC.
-
To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Lawsuit Overview
Settlement Overview
You must register to view and download the Settlement Notice and Settlement Proof.
February 4, 2019 - The court preliminarily approved the settlement.
September 13, 2018 - A stipulation of settlement was filed by the parties.
May 29, 2018 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint.
November 10, 2017 - A motion to dismiss the second amended complaint was filed.
October 13, 2017 - A second amended complaint was filed.
August 24, 2017 - An amended complaint was filed.
May 1, 2017 (Shareholders Foundation) - An investor in shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws by ImmunoCellular Therapeutics in connection with certain allegedly false and misleading statements made between May 1, 2012 through December 11, 2013.
According to the complaint the plaintiff alleges on behalf of purchasers of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) common shares between May 1, 2012 through December 11, 2013, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that between May 1, 2012 through December 11, 2013 the defendants developed a scheme to manipulate and artificially inflate the stock price of ImmunoCellular Therapeutics Ltd and that by virtue of this scheme, the market was conditioned to believe that ImmunoCellular’s clinical studies for ICT-107 were going well as the placement of these fraudulent media reports were often timed to coincide with ImmunoCellular’s announcements of ICT-107, so to have maximum impact upon ImmunoCellular’s share price. T
he plaintiff claims that unbeknownst to the market, beginning in September 2011, ImmunoCellular Therapeutics Ltd hired Lidingo Holdings, LLC, a stock promotional firm to pump up the value of ImmunoCellular Therapeutics Ltd stock and that this endeavor included a campaign of planting phony analyst reports and news articles that fawned over ImmunoCellular Therapeutics Ltd, and that in many cases, these phony media reports were written under aliases, and failed to reveal that ImmunoCellular had complete editorial control over their work.
Then on December 11, 2013, ImmunoCellular Therapeutics Ltd announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival in patients with newly diagnosed glioblastoma multiforme in its randomized, placebo-controlled phase II trial.